leqembi news - Search News

Seeking Alpha on MSN · 1d

Biogen cut to hold by Needham on lack of catalysts, slow Leqembi sales

Needham has downgraded Biogen (NASDAQ:BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the company’s Alzheimer’s drug Leqembi. The investment bank said it doesn’t expect Biogen (BIIB) to return to growth until 2026,

Business Insider · 1d

Needham downgrades Biogen to Hold on lack of share catalysts

Needham downgraded Biogen (BIIB) to Hold from Buy without a price target The firm does not see a meaningful source of upside for the shares

ca.investing.com on MSN · 1d

Needham downgrades Biogen on slow growth of Alzheimer's drug

Investing.com - Needham downgraded Biogen Inc (NASDAQ:BIIB) on Monday, citing slower-than-expected growth for its Alzheimer's drug, Leqembi, and a lack of major catalysts over the next 12 months. The brokerage stated that Leqembi’s sales

Worldcrunch on MSN1d

Leqembi, Is This New Drug The Turning Point In Curing Alzheimer’s?

Lecanemab, marketed as Leqembi, is the first drug targeting the root cause of Alzheimer’s disease to be approved by the ...

EMA changes tune, endorses Eisai and Biogen's Leqembi in restricted Alzheimer's population

Upon reexamination, the European Medicines Agency has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi. | ...

Changing course, European regulators now say Alzheimer’s treatment Leqembi should be approved

Reversing an earlier decision, European regulators recommended that an Alzheimer’s therapy from Eisai and Biogen should be ...

5don MSN

European committee takes a second look at Alzheimer’s drug and now says it should be approved

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

1d

Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026

Biogen downgraded to Hold by Needham amid projected flat revenues until 2026. Leqembi and other new product sales show ...

Pharmalittle: We’re reading about an Alzheimer’s drug about-face, Bavarian Nordic’s views on Trump, and more

Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved ...

Leqembi, Kisunla and Beyond: The Next Wave of Alzheimer’s at CTAD 2024

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

GlobalData on MSN5d

EMA rethinks stance, committee now recommends Leqembi for Alzheimer’s disease

Following a re-evaluation, the EMA has recommended Eisai and Biogen’s Alzheimer’s therapy Leqembi for a subgroup of patients.

EU Gives Green Light: Leqembi on the Verge of Alzheimer's Approval

The EU's drugs regulator recommends approval of Eisai and Biogen's Alzheimer's drug, Leqembi, for patients with early stages ...

Leqembi Okayed for Subset of Early Alzheimer’s Patients

The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results